ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Effective January 21, 2020, Cardax, Inc. (the "Company") entered into and consummated a secured bridge financing of $250,000 through a Secured Convertible Promissory Note (the "Note"). The lender was Harbor Gates Capital, LLC, a Wyoming limited liability company (the "Lender").

The terms of this bridge financing included the following agreements and documents, each entered into as of January 21, 2020:





Securities Purchase Agreement

The Company entered into a Securities Purchase Agreement (the "Purchase Agreement") by and between the Company and the Lender to issue the Note, described below. Under the Purchase Agreement, the Company will issue $25,000 of its restricted shares of common stock, par value $0.001 per share (the "Common Stock") at a price per share equal to the average of the volume weighted average prices of the Common Stock during the five (5) trading days prior to the February 21, 2020.

The Purchase Agreement also included customary representations, warranties, and covenants of the parties to such agreement.

Secured Convertible Promissory Note

The Company issued to the Lender the Note, which included the following terms:

? Principal Amount equal to $262,500, which included an original issue discount

of $12,500, and gross proceeds to the Company of $250,000, which were used by

the Company to pay accrued expenses and for other general corporate purposes.

? Maturity date: June 30, 2020.

? The Note bears a one-time interest charge of 10%, which shall be paid at the

maturity date, unless the Note is converted into shares of Common Stock.

? The Lender may convert any or all of the obligations of the Note into shares of

Common Stock at a price per share (the "Conversion Price") equal to the

following, subject to customary adjustments for stock splits or similar

transactions:

- $14.00 initially, with a one-time reset on February 21, 2020 to a price equal

to the average of the volume weighted average prices of the Common Stock during

the five (5) trading days prior to February 21, 2020, wherein "trading day"

means any day on which the Common Stock is tradable on the OTCQB or on the

principal securities exchange or other securities market on which the Common

Stock is then being traded; or if lower

- From and after the maturity date, a price equal to 70% of the average of the

two lowest daily volume-weighted average prices of the Common Stock for the 15

trading days prior to the Conversion Date.

? The number of shares of Common Stock that may be issued upon conversion is

subject to specified limitations of beneficial ownership that are set forth in

the Note of 4.99% or, at the option of the Lender, 9.99% of the issued and

outstanding shares of Common Stock, which limitations may be decreased or

terminated in the Lender's sole discretion upon 61 days' notice to the Company.

? The Company may prepay the Note in whole or part, subject to specified

prepayment premiums or penalties, equal to 15% for prepayments on or prior to

March 31, 2020; 25% for prepayments on or prior to May 15, 2020; or 30% prior

to June 30, 2020.

? The Note provided for certain customary events of default, including:

- Change of control, being: (1) acquisition of beneficial ownership of 50% or

more of the voting securities of the Company by any individual or legal entity

or group, other than in connection with an underwritten public offering; or (2)

merger or similar transaction where the stockholders of the Company do not own

50% of the aggregate voting power of the surviving entity after such

transaction; or (3) sale of all or substantially all of the assets and the

stockholders of the Company immediately prior to such transaction do not own

50% of the aggregate voting power of the acquiring entity immediately after

such transaction; or (4) a replacement at one time or within a two year period

of more than half of the members of the Board of Directors, if not approved by

a majority of the Board of Directors; or (5) David G. Watumull and David M.

Watumull shall both have been terminated by the Company as Chief Executive

Officer and Chief Operating Officer other than for cause;

- Judgements entered against the Company for more than $500,000 which are not

vacated within 180 days;

- Failure of the Company to comply with the reporting obligations under the

Securities Exchange Act of 1934, as amended;

- Suspension of trading of the Common Stock that continues for 5 trading days; or

- Delisting of the Common Stock on the OTCQB or any other exchange that the

Common Stock is listed for trading that continues for 15 days.

? Upon any event of default, the principal of the Note is increased by 5% and, at

the Lender's option, the maturity of the Note is accelerated.

The Note also included customary representations, warranties, and covenants of the Company.





Security Agreement

The Company granted to the Lender a security interest pursuant to the terms of the Security Agreement (the "Security Agreement") by and between the Company and the Lender in specified collateral, including (as defined under the Uniform Commercial Code): all finished goods, including, without limitation, all inventory; all accounts, together with all instruments, all documents of title representing any of the foregoing, and all right, title, security, and guaranties with respect to each account, including any right of stoppage in transit; and the products and proceeds of all of the foregoing.

The Security Agreement also included customary representations, warranties, and covenants of the parties to such agreement. Upon any Event of Default under the terms of the Security Agreement, the Lender shall have the rights of a secured party under the Uniform Commercial Code, including the right to take possession and sell the collateral and use under a license the intellectual property of the Company related to its inventory.





Subsidiary Guaranty

Cardax Pharma, Inc., the wholly-owned subsidiary of the Company (the "Subsidiary") entered into a Subsidiary Guaranty (the "Subsidiary Guaranty") in favor of the Lender that unconditionally and irrevocably, guarantees to Lender and its successors, endorsees, transferees, and assigns, the prompt and complete payment and performance when due (whether at the stated maturity, by acceleration, or otherwise) of the obligations of the Company under the transaction documents. Such Subsidiary Guaranty also included customary representations, warranties, and covenants of the Subsidiary. Such covenants included that for so long a 67% of the principal amount of the Note is outstanding, the Subsidiary would not:

? Incur or suffer to exist indebtedness or grant or suffer to exist any lien

that, in either case, provides a security interest that is senior to the

security interest granted by the Company on the collateral pledged under the

Security Agreement.

? Enter into any affiliated transaction, other than transactions that are made on

arm's length terms and approved by the majority of the disinterested directors . . .

ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS





Exhibit No.   Description

10.1            Form of Securities Purchase Agreement by and among Cardax, Inc.
              and Harbor Gates Capital, LLC
10.2            Form of Secured Convertible Promissory Note issued by Cardax, Inc.
              to Harbor Gates Capital, LLC
10.3            Form of Security Agreement by and among Cardax, Inc. and Harbor
              Gates Capital, LLC
10.4            Form of Subsidiary Guaranty by and among Cardax Pharma, Inc. and
              Harbor Gates Capital, LLC
10.5            Form of Personal Guaranty of David G. Watumull

© Edgar Online, source Glimpses